THE EVIDENCE
PT-141 research: a central-brain mechanism, two pivotal trials, and a record that is stronger in women than anywhere else.
From the rat and primate pharmacology to the imaged human brain — what each study established, and where its standing ends.
Before the details
The PT-141 research record divides cleanly into three layers. First, the basic pharmacology: PT-141 (bremelanotide) switches on brain receptors called MC3R and MC4R, and animal work showed this changes sexual behavior through the brain rather than through blood vessels [1][2]. Second, the human female evidence: two large trials and a year-long follow-up in premenopausal women with HSDD, plus a brain-scan study that watched the mechanism work [3][4][5]. Third, the older male erectile-dysfunction line, which produced real signals but never an approval for men [1].
Keeping those layers straight is the whole point. A finding in rats is a finding in rats. A signal in men with erectile dysfunction is exactly that — a research signal, not an approved use [1]. The approval lives only in the female-HSDD layer [7]. Each section below states what was measured and in whom.
The central mechanism
PT-141 acts on the brain. It is an agonist at the melanocortin receptors MC3R and MC4R, which are expressed primarily in the central nervous system — concentrated in the hypothalamus and limbic system [1]. By stimulating MC4R in hypothalamic circuits such as the medial preoptic area (a region central to sexual motivation), it is thought to engage dopamine pathways that drive sexual desire [1].
The foundational pharmacology paper showed that systemic administration produced penile erections in rats and nonhuman primates and activated hypothalamic neurons, and produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. The contrast with the familiar erectile-dysfunction pills is mechanistic and complete: those act peripherally on vascular smooth muscle, while PT-141 acts on the neural circuitry of sexual motivation itself [1].
PT-141 peptide: the preclinical female work
The PT-141 peptide earned its female-sexual-function reputation in animal models first. In female rats, the peptide selectively stimulated appetitive, solicitational sexual behaviors — the proceptive, desire-driven kind — without affecting lordosis, pacing, or general motor activity [2]. That selectivity mattered: it was the first reported pharmacological agent acting specifically on appetitive female sexual behavior, and it pointed to central melanocortin systems as regulators of female desire [2].
Not every preclinical result was confirmatory, and the digest reports the nuance. In female Syrian hamsters, MC3R/MC4R messenger RNA was concentrated in dopamine neurons of the ventral tegmental area, but bremelanotide did not change melanocortin-receptor expression in that mesolimbic system and did not enhance sexual reward in a place-preference test — suggesting it may not act on the classic VTA–nucleus-accumbens reward circuit [6]. That is a careful negative finding, and it sits in the record alongside the positive ones.
The human female evidence
The strongest human data is in women, and it is substantial. Two identical Phase 3 trials (RECONNECT, 1,267 premenopausal women with HSDD) showed bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints — desire up by an integrated +0.35 and desire-distress down by −0.33, each P<.001 over 24 weeks [3]. A 52-week open-label extension in 684 women sustained those gains with no new safety signals [4].
The mechanism was then imaged. In a placebo-controlled crossover fMRI study of 31 women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli, enhancing amygdala–insula connectivity [5]. A 2026 systematic review and meta-analysis confirmed improvements in total Female Sexual Function Index scores and the desire and arousal subscales across pooled trials [12], while a 2026 ClinicalTrials.gov analysis named bremelanotide among the most-studied HSDD pharmacotherapies but flagged heterogeneity and inconsistent safety reporting across studies [13].
PT-141 for men
The male erectile-dysfunction line is part of the history and is read as off-label research throughout this digest. PT-141 was first developed as a nasal spray for erectile dysfunction and female sexual dysfunction, with a completed Phase IIb erectile-dysfunction trial and Phase III trials planned at the time [9]. The foundational pharmacology likewise documented rapid, dose-dependent erectile activity in men with erectile dysfunction [1].
But that program did not lead to an approval for men, and the intranasal route was later set aside for pharmacokinetic variability in favor of subcutaneous dosing [9]. One older male-ED salvage study (Safarinejad & Hosseini, 2008) received a 2023 Expression of Concern and should be treated as disputed [appears in references]. The takeaway: male use of PT-141 is off-label and investigational, not approved — the data is real, the approval is not [7].
The debates worth carrying
A complete research summary keeps the criticism in view. Independent re-analyses argue the trial effects on desire and distress, while significant, are small, and question their clinical meaningfulness and the outcome measures used; one notes bremelanotide produced no additional enjoyable sexual experiences on average and argues the approval leaned on regulatory precedent [11]. Reviews of HSDD itself flag a lack of diagnostic consensus and a debate about the medicalization of low desire [8].
There are also off-label populations with no efficacy data: a clinician guide to managing HSDD in transgender women lists bremelanotide among centrally acting options while explicitly noting efficacy evidence in that group is lacking [14]. The pattern across the literature is consistent — a genuine, approved, central-mechanism drug for one narrow group, surrounded by uses where the evidence thins or runs out.